Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Serum Biomarkers In Patients With Mesothelioma And Pleural Plaques And Healthy Subjects Exposed To Naturally Occurring Asbestos

Mehmet Bayram, Isa Dongel, A. Akbaş, I. Benli, M. Akkoyunlu, N. Bakan
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PurposeThis study investigated the diagnostic accuracy of the serum biomarkers osteopontin and mesothelin in discriminating mesothelioma patients from those with other, benign conditions and whether levels of the biomarkers differed in subjects who had inhaled naturally occurring asbestos compared with a non-exposed control group.MethodsThis cross-sectional study studied 24 subjects with mesothelioma, 279 subjects with pleural plaques, 123 “healthy exposed,” and 120 control subjects. The Kruskal–Wallis test was performed to compare mesothelin and osteopontin levels of the groups, and receiver operating characteristics curves were generated to determine diagnostic yields of both biomarkers. Multiple linear regression analyses were used to identify associated covariates with osteopontin and mesothelin levels.ResultsSerum osteopontin and mesothelin levels were higher in mesothelioma than in benign asbestos-related diseases and healthy exposed subjects. Both biomarker levels were independently associated with mesothelioma, age and smoking pack years. Mesothelin levels were also associated with body mass index. The sensitivity and specificity of osteopontin in distinguishing mesothelioma from the three other groups were 75 and 86 %, respectively; those of mesothelin were 58 and 83 %, respectively. The sensitivity and specificity to discriminate mesothelioma from pleural plaques and healthy subjects were 93 and 73 %, respectively, if osteopontin and mesothelin levels were higher than their optimal cut off levels.ConclusionsThe combination of serum osteopontin and mesothelin levels can help to distinguish mesothelioma from benign asbestos-related diseases and asbestos-exposed subjects.
This paper references
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1136/oem.45.12.838
An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos.
Y. Bariş (1988)
10.1016/j.rmed.2013.03.006
Is living close to ophiolites related to asbestos related diseases? Cross-sectional study.
Isa Döngel (2013)
10.1158/1055-9965.EPI-08-0150
Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer
Kimberly A Lowe (2008)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin.
K. Shiomi (2011)
Mesothelioma in Cyprus.
K. Mcconnochie (1989)
10.1158/1078-0432.CCR-08-0360
Osteopontin Levels in an Asbestos-Exposed Population
E. Park (2009)
10.1097/MCP.0b013e328354acfe
Asbestos-related pleural disease
R. Myers (2012)
10.1164/AJRCCM.158.6.9712119
Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage.
P. Dumortier (1998)
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
N. Fedarko (2001)
10.1289/ehp.1002862
Pleural Mesothelioma in New Caledonia: Associations with Environmental Risk Factors
F. Baumann (2011)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1097/JTO.0b013e31821e1c08
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1097/00063198-200007000-00020
Environmental asbestos exposure and mesothelioma
M. Orenstein (2000)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.1080/10937404.2011.556045
Applying Definitions of “Asbestos” to Environmental and “Low-Dose” Exposure Levels and Health Effects, Particularly Malignant Mesothelioma
B. Case (2011)
10.1007/s00204-010-0580-2
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos
M. Gube (2010)
10.1373/clinchem.2008.121913
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.
K. Hollevoet (2009)
Combined CA 125 and mesothelin levels for the diagnosis of malignant mesotheli
J Creaney (2007)
10.1016/j.lungcan.2011.02.007
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
J. Creaney (2011)
10.3978/j.issn.2072-1439.2013.04.19
The continual search for ideal biomarkers for mesothelioma: the hurdles.
F. Brims (2013)
10.1016/J.THORSURG.2004.06.011
Epidemiology, biologic behavior, and natural history of mesothelioma.
L. Zellos (2004)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1016/j.cyto.2012.12.028
Osteopontin is increased in the bronchoalveolar lavage fluid and bronchial tissue of smoking asthmatics.
K. Samitas (2013)
10.1378/CHEST.126.2.617
Decreasing prevalence of pleural calcifications among Metsovites with nonoccupational asbestos exposure.
C. Manda-Stachouli (2004)
10.1378/chest.11-2727
High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites.
Mehmet Bayram (2013)
Les mésothéliomes environnementaux en Corse du nord-est
F. Rey (1993)
10.1007/s10653-013-9518-y
The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey
S. Berk (2013)
[Environmental mesotheliomas in northeast Corsica].
F. Rey (1993)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1164/RCCM.200412-1731OC
Residential proximity to naturally occurring asbestos and mesothelioma risk in California.
X. Pan (2005)
10.1289/EHP.01109915
Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy.
C. Magnani (2001)



This paper is referenced by
10.3389/fonc.2019.00740
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
I. Cavallari (2019)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.1016/j.jtho.2017.04.002
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
10.3390/cancers12051262
Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways
A. Di Gilio (2020)
10.1111/resp.13557
Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension
M. Mura (2019)
10.1007/s12199-015-0477-z
Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population
M. Yu (2015)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
Chapter 12 Biomarkers of Response to Asbestos Exposure
Blair ()
10.3389/fonc.2020.00445
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
L. Ferrari (2020)
10.1186/s12931-017-0546-5
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives
L. Cortes-Dericks (2017)
10.4155/bio.15.53
Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure.
Clementina A. Mesaros (2015)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.5772/intechopen.89438
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
10.1016/j.shaw.2020.07.009
Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders
E. Park (2020)
10.2217/bmm-2017-0087
Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure.
Rengyi Xu (2017)
10.1007/978-3-319-53560-9_12
Biomarkers of Response to Asbestos Exposure
C. Mesaros (2017)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.3390/ijerph17082636
Asbestos Air Pollution: Description of a Mesothelioma Cluster Due to Residential Exposure from an Asbestos Cement Factory
L. Vimercati (2020)
10.3390/cells8080815
Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight
Anne-Sophie Lamort (2019)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1158/1055-9965.EPI-20-0083
Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network
H. Pass (2020)
Semantic Scholar Logo Some data provided by SemanticScholar